Pasithea Therapeutics Corp Stock Alpha and Beta Analysis
| KTTA Stock | USD 2.90 0.11 3.65% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Pasithea Therapeutics Corp. It also helps investors analyze the systematic and unsystematic risks associated with investing in Pasithea Therapeutics over a specified time horizon. Remember, high Pasithea Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Pasithea Therapeutics' market risk premium analysis include:
Beta 0.51 | Alpha (0.40) | Risk 9.36 | Sharpe Ratio (0.03) | Expected Return (0.33) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Pasithea |
Pasithea Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Pasithea Therapeutics market risk premium is the additional return an investor will receive from holding Pasithea Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Pasithea Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Pasithea Therapeutics' performance over market.| α | -0.4 | β | 0.51 |
Pasithea Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Pasithea Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Pasithea Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Pasithea Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Pasithea Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Pasithea Therapeutics shares will generate the highest return on investment. By understating and applying Pasithea Therapeutics stock market price indicators, traders can identify Pasithea Therapeutics position entry and exit signals to maximize returns.
Pasithea Therapeutics Return and Market Media
The median price of Pasithea Therapeutics for the period between Fri, Aug 30, 2024 and Thu, Nov 28, 2024 is 3.99 with a coefficient of variation of 17.67. The daily time series for the period is distributed with a sample standard deviation of 0.73, arithmetic mean of 4.15, and mean deviation of 0.59. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Tiago Marques of 5000 shares of Pasithea Therapeutics at 1.0 subject to Rule 16b-3 | 09/13/2024 |
2 | Pasithea Therapeutics Announces 5 Million Private Placement Priced At-The-Market Under Nasdaq Rules | 09/26/2024 |
3 | Pasithea Therapeutics drops 19 percent on 5M private placement | 09/27/2024 |
4 | Acquisition by Novak Alfred J of 5000 shares of Pasithea Therapeutics at 8.13 subject to Rule 16b-3 | 10/17/2024 |
5 | Acquisition by Dumesnil Simon of 10000 shares of Pasithea Therapeutics at 1.07 subject to Rule 16b-3 | 10/28/2024 |
6 | ARMISTICE CAPITAL, LLC Acquires New Stake in Pasithea Therapeutics Corp | 11/15/2024 |
7 | Pasithea Therapeutics Corporation Enters into At The Market Offering Agreement with H.C. Wainwright Co. LLC | 11/27/2024 |
About Pasithea Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Pasithea or other stocks. Alpha measures the amount that position in Pasithea Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2022 | 2023 (projected) | PB Ratio | 203.23 | 0.38 | 0.4 | Capex To Depreciation | 15.59 | 66.06 | 5.3E-5 |
Pasithea Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Pasithea Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Pasithea Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Pasithea Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Pasithea Therapeutics. Please utilize our Beneish M Score to check the likelihood of Pasithea Therapeutics' management manipulating its earnings.
| 12th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Pasithea Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Pasithea Therapeutics Backtesting, Pasithea Therapeutics Valuation, Pasithea Therapeutics Correlation, Pasithea Therapeutics Hype Analysis, Pasithea Therapeutics Volatility, Pasithea Therapeutics History and analyze Pasithea Therapeutics Performance. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Pasithea Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.